The FDA granted orphan-drug status to OXiGENE's OXi4503, an experimental drug for acute myelogenous leukemia. The drug has demonstrated strong tumor-fighting activity in preclinical and clinical trials, CEO Peter Langecker said. OXiGENE plans to apply for orphan drug designation in the European Union. An early-stage trial is being backed by the Leukemia & Lymphoma Society.
FDA gives orphan-drug designation to OXiGENE's leukemia drug
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||